Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Radnet ( (RDNT) ) is now available.
On January 30, 2026, RadNet filed a prospectus supplement with the SEC to register for resale up to 190,924 shares of its common stock by the Cimar Sellers, who are designated as selling stockholders. These shares represent the non-cash portion of the consideration paid for RadNet’s acquisition of all shares of Cimar (UK) Limited, completed on November 10, 2025, through its Netherlands-based subsidiary DH AI International Holdings, B.V., highlighting RadNet’s continued use of equity to finance strategic technology acquisitions and integrate Cimar’s capabilities into its broader imaging platform.
The most recent analyst rating on (RDNT) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Radnet stock, see the RDNT Stock Forecast page.
Spark’s Take on RDNT Stock
According to Spark, TipRanks’ AI Analyst, RDNT is a Neutral.
The score is driven primarily by moderate financial performance with strong cash flow but ongoing profitability and leverage concerns. The latest earnings call was notably positive with record results and raised guidance, while technicals are mixed and valuation is pressured by loss-making earnings and no dividend support.
To see Spark’s full report on RDNT stock, click here.
More about Radnet
RadNet, Inc. operates in the medical imaging and diagnostic services sector, providing imaging solutions and related technologies, and is expanding its capabilities through acquisitions such as Cimar (UK) Limited to strengthen its position in cloud-based imaging and AI-enabled platforms.
Average Trading Volume: 868,560
Technical Sentiment Signal: Buy
Current Market Cap: $5.54B
Find detailed analytics on RDNT stock on TipRanks’ Stock Analysis page.